@article{4ac0bca148c843fca1a6bb1a9697b43b,
title = "Phase II evaluation of carboplatin in advanced endometrial carcinoma",
abstract = "Carboplatin was administered by iv bolus every 28 days to 26 patients who had extensive metastatic or recurrent endometrial adenocarcinoma and no prior chemotherapy exposure. The dose level was 400 mg/m2 in 5 patients with and 4 patients without prior irradiation and 300 mg/m2 in 16 patients with prior pelvic irradiation. Partial disease regressions were seen in 28% of patients (95% confidence interval, 12%-50%), with a median response duration of 129 days. Median survival of all patients was 215 days; median time to disease progression for all patients was 117 days. We conclude that carboplatin is an active agent in advanced endometrial carcinoma and is worthy of further investigation in single-agent and combination chemotherapy, [J Natl Cancer Inst 1988;80:276-278]",
author = "Long, {H. J.} and Pfeifle, {D. M.} and Wieand, {H. S.} and Krook, {J. E.} and Edmonson, {J. H.} and Buckner, {J. C.}",
note = "Funding Information: 2A collaborative study of the Mayo Clinic and North Central Cancer Treatment Group, Rochester, MN; supported in part by Public Health Service grants CA-15083 and CA-25224 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Additional participating investigators include: The Duluth Clinic Community Clinical Oncology Program (CCOP), Duluth, MN (ft J. Dalton, ft D. Neidringhausy, Fargo Clinic CCOP, Fargo, ND (P. S. EneUy, Oncology Associates of Cedar Rapids, Cedar Rapids, IA (M Wiesenftidy, Sioux Falls Community Cancer Consortium CCOP, Sioux Falls, SD (Z_ K. Tschetter, ft F. Marschkey, University of Nebraska Medical Center, Omaha, NE (J. A. Mailliard, S. C. Soren-son); Grand Forks Clinic, Ltd., Grand Forks, ND (/. A. Laurie). •{"}Division of Medical Oncology (H. J. Long. J. H. Edmonson, J. C. Bucknef) and Cancer Center Statistics Unit (H. S. Wleand), Mayo Clinic, Rochester, MN. 4Quain and Ramstad Clinic, Bismarck, ND. 3Duluth Clinic CCOP, Duluth, MN. * Correspondence to: North Central Cancer Treatment Group, Operations Office, 200 First St. S.W., Rochester, MN 55905. Funding Information: Supported by Public Health Service grant CA-42705 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.",
year = "1988",
month = apr,
day = "20",
doi = "10.1093/jnci/80.4.276",
language = "English (US)",
volume = "80",
pages = "276--278",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",
}